000284361 001__ 284361
000284361 005__ 20260130151745.0
000284361 0247_ $$2doi$$a10.1007/s00702-025-03096-7
000284361 0247_ $$2pmid$$apmid:41484430
000284361 0247_ $$2ISSN$$a0375-9245
000284361 0247_ $$2ISSN$$a0022-3026
000284361 0247_ $$2ISSN$$a0300-9564
000284361 0247_ $$2ISSN$$a1435-1463
000284361 037__ $$aDZNE-2026-00129
000284361 041__ $$aEnglish
000284361 082__ $$a610
000284361 1001_ $$00000-0002-2854-4179$$aFanciulli, Alessandra$$b0
000284361 245__ $$aHow to treat cardiovascular autonomic failure in Parkinson's disease.
000284361 260__ $$aWien [u.a.]$$bSpringer$$c2026
000284361 3367_ $$2DRIVER$$aarticle
000284361 3367_ $$2DataCite$$aOutput Types/Journal article
000284361 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1769782587_8942$$xReview Article
000284361 3367_ $$2BibTeX$$aARTICLE
000284361 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284361 3367_ $$00$$2EndNote$$aJournal Article
000284361 520__ $$aCardiovascular autonomic failure is a frequent non-motor feature of Parkinson's disease (PD) that affects up to one third of individuals from the premotor to the advanced stages of the disease, with major diagnostic, therapeutic and prognostic implications. It may manifest with orthostatic, post-prandial or exercise-induced hypotension, as well as hypertensive episodes in the supine position during wakefulness or nocturnal sleep. Hypotensive episodes may remain asymptomatic or manifest with symptoms of end-organ hypoperfusion in the upright position, after meals or during exertion that may include lightheadedness, blurred vision, cognitive slowness, shuffling gait, back pain, fatigue or, in severe cases, syncope. Supine and nocturnal hypertension are likewise often asymptomatic, yet may cause nocturnal polyuria, and disrupt sleep through frequent nocturnal toilet visits. Bedside screening for cardiovascular autonomic failure relies on targeted history taking, eventually supported by validated questionnaires, and supine to standing heart rate and blood pressure measurements. A more detailed assessment is obtained with cardiovascular autonomic function tests under continuous, non-invasive, hemodynamic monitoring, complemented by 24-hours ambulatory blood pressure monitoring and home blood pressure diaries. Hypotensive episodes are managed by addressing potential triggers, such as infections, anemia, dehydration and polypharmacy, followed by a stepwise implementation of behavioral, non-pharmacological and pharmacological strategies. Individuals with orthostatic hypotension should be constantly monitored for concomitant supine and nocturnal hypertension, especially if treatment with pressor agents has been recently started. Hypertensive episodes are likewise treated in a stepwise fashion with preventive, non-pharmacological and pharmacological measures, prioritizing hypotension control during daytime and mitigating hypertension overnight.
000284361 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000284361 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000284361 650_7 $$2Other$$aNocturnal hypertension
000284361 650_7 $$2Other$$aOrthostatic hypotension
000284361 650_7 $$2Other$$aParkinson’s disease
000284361 650_7 $$2Other$$aPost-prandial hypotension
000284361 650_7 $$2Other$$aSupine hypertension
000284361 650_2 $$2MeSH$$aHumans
000284361 650_2 $$2MeSH$$aParkinson Disease: complications
000284361 650_2 $$2MeSH$$aAutonomic Nervous System Diseases: etiology
000284361 650_2 $$2MeSH$$aAutonomic Nervous System Diseases: therapy
000284361 650_2 $$2MeSH$$aAutonomic Nervous System Diseases: diagnosis
000284361 650_2 $$2MeSH$$aCardiovascular Diseases: therapy
000284361 650_2 $$2MeSH$$aCardiovascular Diseases: etiology
000284361 650_2 $$2MeSH$$aCardiovascular Diseases: diagnosis
000284361 7001_ $$00000-0003-1714-5305$$aLeys, Fabian$$b1
000284361 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b2
000284361 7001_ $$00000-0002-8574-3297$$aJost, Wolfgang H$$b3
000284361 773__ $$0PERI:(DE-600)1481655-6$$a10.1007/s00702-025-03096-7$$gVol. 133, no. 2, p. 215 - 228$$n2$$p215 - 228$$tJournal of neural transmission$$v133$$x0375-9245$$y2026
000284361 8564_ $$uhttps://pub.dzne.de/record/284361/files/DZNE-2026-00129.pdf$$yRestricted
000284361 8564_ $$uhttps://pub.dzne.de/record/284361/files/DZNE-2026-00129.pdf?subformat=pdfa$$xpdfa$$yRestricted
000284361 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000284361 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000284361 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284361 915__ $$0StatID:(DE-HGF)3002$$2StatID$$aDEAL Springer$$d2025-01-02$$wger
000284361 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEURAL TRANSM : 2022$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-02
000284361 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-02
000284361 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000284361 980__ $$ajournal
000284361 980__ $$aEDITORS
000284361 980__ $$aVDBINPRINT
000284361 980__ $$aI:(DE-2719)1111015
000284361 980__ $$aUNRESTRICTED